RAPT Therapeutics, Inc., a California-based clinical-stage immunology-based biopharmaceutical company, has made significant strides in its mission to discover, develop, and commercialize oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead drug candidate, RPT193, is an inflammation drug that selectively inhibits the migration of type 2 T helper cells into inflamed tissues through its C-C motif chemokine receptor 4 (CCR4) antagonist properties. RAPT's other lead drug candidate, FLX475, is an oral small molecule CCR4 antagonist that is currently in Phase 1/2 clinical trials, being tested as a monotherapy and in combination with pembrolizumab in advanced cancer patients. RAPT Therapeutics is also focusing on the development of hematopoietic progenitor kinase 1 inhibitor. RAPT Therapeutics was formerly known as FLX Bio, Inc. and changed its name in May 2019. Founded in 2015, RAPT Therapeutics is a promising player in the field of immunology-based biopharmaceuticals.